A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
A phase 1/2 trial of Zipalertinib in non-small-cell lung cancer and small-cell lung cancer, run by Cullinan Therapeutics Inc., active and no longer recruiting.
Overview
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04036682 by Cullinan Therapeutics Inc., with 284 participants planned, started 2019-10-31 and due to reach its primary completion in 2025-10-13. Interventions recorded: CLN-081. Conditions listed: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Phase
Phase 1/2
Sponsor
Cullinan Therapeutics Inc.
Registry
Enrolled
284
Similar pages
not linked directly; found by shared links- TrialREZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Shares Zipalertinib, Non-small-cell lung cancer.
- TrialA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Shares Zipalertinib, Non-small-cell lung cancer.